iHuman Inc. (IH) director discloses existing option grants in Form 3 filing

Rhea-AI Filing Summary

iHuman Inc. director Li Xuenan reported existing option holdings in a Form 3. The filing shows two option grants, each covering 27,000 underlying Class A ordinary shares at an exercise price of 0.0500 per share. One grant expires on November 30, 2030 and fully vested by October 8, 2023. The second grant expires on December 15, 2032 and vests in four equal annual installments after its December 15, 2022 grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Li Xuenan

Role Director

Type	Security	Shares	Price	Value
holding	Options	--	--	--
holding	Options	--	--	--

Holdings After Transaction: Options — 27,000 shares (Direct)

Footnotes (1)

1. These options were granted on November 30, 2020 and vested over a three-year period, with 33.33% of the options vesting on October 8, 2021, 33.33% on October 8, 2022, and the remaining 33.34% on October 8, 2023. These options were granted on December 15, 2022 and vest in equal installments over a four-year period, with 25% of the options vest on each anniversary after the grant date.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Li Xuenan

(Last) (First) (Middle)

ORIENTAL PLAZA, TOWER E3, 3F

ONE EAST CHANG AN AVENUE

(Street)

BEIJING 100738

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
iHuman Inc. [ IH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(1)	11/30/2030	Class A ordinary shares	27,000	$0.05	D
Options	(2)	12/15/2032	Class A ordinary shares	27,000	$0.05	D

Explanation of Responses:

1. These options were granted on November 30, 2020 and vested over a three-year period, with 33.33% of the options vesting on October 8, 2021, 33.33% on October 8, 2022, and the remaining 33.34% on October 8, 2023.

2. These options were granted on December 15, 2022 and vest in equal installments over a four-year period, with 25% of the options vest on each anniversary after the grant date.

	/s/ Xuenan Li	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does iHuman Inc. (IH) director Li Xuenan report in this Form 3?

The Form 3 reports Li Xuenan’s existing option holdings in iHuman Inc. It lists two option grants over Class A ordinary shares, detailing their underlying share amounts, exercise price, vesting schedules, and expiration dates, but shows no new buy or sell transactions.

How many iHuman Inc. (IH) shares underlie Li Xuenan’s reported options?

The filing shows options over 27,000 underlying Class A ordinary shares in one grant and another 27,000 in a second grant. These totals indicate two separate option packages, each linked to future share delivery upon exercise at the stated price.

What are the exercise price and expiration dates of Li Xuenan’s iHuman (IH) options?

Both option grants carry an exercise price of 0.0500 per share. One grant expires on November 30, 2030, while the other expires on December 15, 2032, defining the periods during which the options can potentially be exercised.

How do the iHuman Inc. (IH) options held by Li Xuenan vest over time?

The first option grant vested over three years, with 33.33% vesting on October 8, 2021, another 33.33% on October 8, 2022, and 33.34% on October 8, 2023. The second grant vests 25% on each anniversary after the December 15, 2022 grant date.

Does this iHuman (IH) Form 3 show any insider buying or selling activity?

The Form 3 does not show insider buying or selling activity. It classifies the entries as holdings, with unknown transaction codes, and the transaction summary indicates zero buy, sell, acquire, or dispose counts, focusing solely on reporting existing option positions.